IBI355
- Generic Name
- IBI355
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
Phase 1
Active, not recruiting
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- Drug: IBI355 placebo
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06484855
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Safety and Tolerability of IBI355 in Healthy Volunteers
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06416787
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
Safety and Tolerance Study of IBI355 in Health Volunteers
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT06110338
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath